VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: Yahoo! Finance
Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 23%. Looking ahead, revenue is forecast to grow 94% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are up 19% from a week ago. We should say that we've discovered 6 warning signs for VYNE Therapeutics (3 are significant!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your obj
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
- VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET InhibitorGlobeNewswire
- VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
VYNE
Sec Filings
- 12/23/24 - Form 8-K
- 12/19/24 - Form S-8
- 12/13/24 - Form 4
- VYNE's page on the SEC website